Clinical pharmacology and therapeutic applications of the new oral converting enzyme inhibitor, enalapril
- 31 May 1985
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 109 (5) , 1085-1089
- https://doi.org/10.1016/0002-8703(85)90252-2
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Influence of Food on the Bioavailability of EnalaprilJournal of Pharmaceutical Sciences, 1984
- Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertensionThe American Journal of Cardiology, 1984
- Humoral and Renal Effects of MK-421 (Enalapril) in Hypertensive SubjectsJournal of Cardiovascular Pharmacology, 1983
- Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patientsProstaglandins, Leukotrienes and Medicine, 1983
- Enalapril Maleate (MK-421), a Potent, Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in ManDrug Metabolism Reviews, 1983
- Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.British Journal of Clinical Pharmacology, 1982
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982
- Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.British Journal of Clinical Pharmacology, 1982
- A new class of angiotensin-converting enzyme inhibitorsNature, 1980
- Disposition of captopril in normal subjectsClinical Pharmacology & Therapeutics, 1980